Inclusion Criteria:

          1. Male or female participants age ≥ 18 years of age at the time of informed consent.

          2. Ability to provide and understand written informed consent prior to any study
             procedures.

          3. Histologically or cytologically confirmed diagnosis of metastatic uveal melanoma
             (mUM).

          4. Surgically sterile participants or participants of child-bearing potential who agree
             to use highly effective methods of contraception during study dosing and for 6 months
             after last dose of study drug.

          5. Human leukocyte antigen (HLA)-A*0201 positive.

          6. ECOG Performance Status of 0 or 1 at Screening.

          7. Phase 2 will include participants with previously treated uveal melanoma in the
             metastatic setting.

        Exclusion Criteria:

          1. Presence of symptomatic or untreated central nervous system (CNS) metastases, or CNS
             metastases that require doses of corticosteroids.

          2. History of severe hypersensitivity reactions to other biologic drugs or monoclonal
             antibodies.

          3. Participants with any out-of-range laboratory values.

          4. Clinically significant cardiac disease or impaired cardiac function.

          5. Active infection requiring systemic antibiotic therapy.

          6. Known history of HIV infection.

          7. Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection per institutional
             protocol.

          8. Participants receiving systemic treatment with systemic steroid therapy or any other
             immunosuppressive medication at any dose level that would interfere with the action of
             the study drugs in the opinion of the investigator.

          9. Malignant disease, other than that being treated in this study.

         10. Any medical condition that would, in the investigator's judgment, prevent
             participation in the clinical study due to safety concerns, compliance with clinical
             study procedures or interpretation of study results.

         11. Presence of NCI CTCAE ≥ grade 2 toxicity (except alopecia, peripheral neuropathy and
             ototoxicity, which are excluded if ≥ NCI CTCAE grade 3) due to prior cancer therapy.

         12. Pregnant, likely to become pregnant, or lactating women.